# Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes

> **NCT01602003** · PHASE3 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 425 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LC15-0444 25mg bid
- **DRUG:** LC15-0444 50mg qd
- **DRUG:** Sitagliptin 100mg qd

## Key facts

- **NCT ID:** NCT01602003
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-06
- **Final completion:** 2012-05
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2012-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602003, "Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01602003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*